Literature DB >> 12111441

Cerebrospinal fluid levels of thiamine in patients with Alzheimer's disease.

J A Molina1, F J Jiménez-Jiménez, A Hernánz, E Fernández-Vivancos, S Medina, F de Bustos, C Gómez-Escalonilla, Y Sayed.   

Abstract

Thiamine is an essential cofactor for several important enzymes involved in brain oxidative metabolism, such as the alpha-ketoglutarate dehydrogenase complex (KGDHC), pyruvate-dehydrogenase complex (PDHC), and transketolase. Some investigators reported decreased thiamine-diphosphate levels and decreased activities of KGDHC, pyruvate-dehydrogenase complex and transketolase in the brain tissue of Alzheimer's disease (AD) patients. We measured cerebrospinal (CSF) levels of thiamine-diphosphate, thiamine-monophosphate, free thiamine, and total thiamine, using ion-pair reversed phase high performance liquid chromatography, in 33 patients with sporadic AD and 32 matched controls. The mean CSF levels of thiamine-derivatives did not differ significantly from those of controls, while the mean plasma levels of thiamine-diphosphate, free and total thiamine were significantly lower in the AD-patient group. CSF and plasma thiamine levels were not correlated with age, age at onset, duration of the disease, and scores of the MiniMental State Examination, with the exception of plasma thiamine-diphosphate with MiniMental State Examination (r = 0.41, p < 0.05) in the AD-patients group. CSF and plasma values did not predict dementia progression, assessed with the MiniMental State Examination scores. These results suggest that CSF thiamine levels are not related with the risk for and the progression of AD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111441     DOI: 10.1007/s007020200087

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  7 in total

1.  Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial.

Authors:  Gary E Gibson; José A Luchsinger; Rosanna Cirio; Huanlian Chen; Jessica Franchino-Elder; Joseph A Hirsch; Lucien Bettendorff; Zhengming Chen; Sarah A Flowers; Linda M Gerber; Thomas Grandville; Nicole Schupf; Hui Xu; Yaakov Stern; Christian Habeck; Barry Jordan; Pasquale Fonzetti
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

2.  Design of a randomized placebo controlled trial of high dose intravenous thiamine for the prevention of delirium in allogeneic hematopoietic stem cell transplantation.

Authors:  Zev M Nakamura; Allison M Deal; Donald L Rosenstein; Laura J Quillen; Stephanie A Chien; William A Wood; Thomas C Shea; Eliza M Park
Journal:  Contemp Clin Trials       Date:  2020-06-30       Impact factor: 2.226

3.  Thiamine status in humans and content of phosphorylated thiamine derivatives in biopsies and cultured cells.

Authors:  Marjorie Gangolf; Jan Czerniecki; Marc Radermecker; Olivier Detry; Michelle Nisolle; Caroline Jouan; Didier Martin; Frédéric Chantraine; Bernard Lakaye; Pierre Wins; Thierry Grisar; Lucien Bettendorff
Journal:  PLoS One       Date:  2010-10-25       Impact factor: 3.240

4.  Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy.

Authors:  Victor Tapias; Shari Jainuddin; Manuj Ahuja; Cliona Stack; Ceyhan Elipenahli; Julie Vignisse; Meri Gerges; Natalia Starkova; Hui Xu; Anatoly A Starkov; Lucien Bettendorff; Dmitry M Hushpulian; Natalya A Smirnova; Irina G Gazaryan; Navneet A Kaidery; Sushama Wakade; Noel Y Calingasan; Bobby Thomas; Gary E Gibson; Magali Dumont; M Flint Beal
Journal:  Hum Mol Genet       Date:  2018-08-15       Impact factor: 6.150

5.  Thiamine diphosphate in whole blood, thiamine and thiamine monophosphate in breast-milk in a refugee population.

Authors:  Wolfgang Stuetz; Verena Ilona Carrara; Rose McGready; Sue Jean Lee; Hans Konrad Biesalski; François Henry Nosten
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

6.  Integrating transcriptomics with metabolic modeling predicts biomarkers and drug targets for Alzheimer's disease.

Authors:  Shiri Stempler; Keren Yizhak; Eytan Ruppin
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

Review 7.  A Bird's-Eye View of the Multiple Biochemical Mechanisms that Propel Pathology of Alzheimer's Disease: Recent Advances and Mechanistic Perspectives on How to Halt the Disease Progression Targeting Multiple Pathways.

Authors:  Caleb Vegh; Kyle Stokes; Dennis Ma; Darcy Wear; Jerome Cohen; Sidhartha D Ray; Siyaram Pandey
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.